This Level 3 case-control study tested whether adding autologous platelet-rich fibrin (PRGF) to standard open Achilles tendon repair accelerates healing in athletes. Six PRGF-treated athletes were retrospectively compared with 6 matched athletes who underwent identical surgery without PRGF. Outcomes included ankle range of motion recovery, return to running, return to training, wound complications, and long-term ultrasound cross-sectional area.
Wound healing complications are the most feared consequence of open Achilles repair, estimated at 15–20% in the literature. This paper was one of the first to report that augmenting repair with autologous platelet-rich fibrin could simultaneously reduce complications and compress return-to-sport timelines by roughly 7 weeks.
For an athletic patient asking how soon they can return to training, these numbers are compelling: 14 weeks vs 21 weeks is the difference between a single season lost and a full year out.
Treat these results as hypothesis-generating, not practice-changing. Six patients per group, a retrospective design, unequal ultrasound follow-up intervals, and sport-mix differences between groups all limit confidence. The authors themselves call for an RCT.
The mechanistic framework here is what has lasting value: platelet-rich preparations deliver a concentrated, leukocyte-free pool of growth factors (TGF-β1, PDGF-AB, VEGF, HGF, EGF) in a fibrin scaffold that mimics natural expression kinetics. This biological rationale underlies the entire PRP literature that followed, making this paper foundational reading for understanding why platelet therapies are used in tendon surgery — even as the clinical evidence base continues to mature.
This Level 3 case-control study tested whether adding autologous platelet-rich fibrin (PRGF) to standard open Achilles tendon repair accelerates healing in athletes. Six PRGF-treated athletes were retrospectively compared with 6 matched athletes who underwent identical surgery without PRGF. Outcomes included ankle range of motion recovery, return to running, return to training, wound complications, and long-term ultrasound cross-sectional area.
Wound healing complications are the most feared consequence of open Achilles repair, estimated at 15–20% in the literature. This paper was one of the first to report that augmenting repair with autologous platelet-rich fibrin could simultaneously reduce complications and compress return-to-sport timelines by roughly 7 weeks.
For an athletic patient asking how soon they can return to training, these numbers are compelling: 14 weeks vs 21 weeks is the difference between a single season lost and a full year out.
Treat these results as hypothesis-generating, not practice-changing. Six patients per group, a retrospective design, unequal ultrasound follow-up intervals, and sport-mix differences between groups all limit confidence. The authors themselves call for an RCT.
The mechanistic framework here is what has lasting value: platelet-rich preparations deliver a concentrated, leukocyte-free pool of growth factors (TGF-β1, PDGF-AB, VEGF, HGF, EGF) in a fibrin scaffold that mimics natural expression kinetics. This biological rationale underlies the entire PRP literature that followed, making this paper foundational reading for understanding why platelet therapies are used in tendon surgery — even as the clinical evidence base continues to mature.